EA200400994A1 - Новые 1,2,3-замещенные производные индолизина, являющиеся ингибиторами факторов роста фибробластов, способ их получения и фармацевтические композиции, содержащие их - Google Patents

Новые 1,2,3-замещенные производные индолизина, являющиеся ингибиторами факторов роста фибробластов, способ их получения и фармацевтические композиции, содержащие их

Info

Publication number
EA200400994A1
EA200400994A1 EA200400994A EA200400994A EA200400994A1 EA 200400994 A1 EA200400994 A1 EA 200400994A1 EA 200400994 A EA200400994 A EA 200400994A EA 200400994 A EA200400994 A EA 200400994A EA 200400994 A1 EA200400994 A1 EA 200400994A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alk
nrr
coor
indolysine
inhibitors
Prior art date
Application number
EA200400994A
Other languages
English (en)
Other versions
EA007902B1 (ru
Inventor
Ален Бадорк
Франсуаза Боно
Мари-Франсуаза Борде
Натали Гийо
Жан-Марк Эрбер
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Publication of EA200400994A1 publication Critical patent/EA200400994A1/ru
Publication of EA007902B1 publication Critical patent/EA007902B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Это изобретение относится к соединениям формулы (I)в которой Rпредставляет собой OH, (C-C)алкокси, карбоксил, (C-C)алкоксикарбонил, -NRR, -NH-SO-Alk, -NH-SO-Ph, -NH-CO-Ph, -N(Alk)-CO-Ph, -NH-CO-NH-Ph, -NH-CO-Alk, -NH-CO-Alk, -O-(CH)-cAlk, -O-Alk-COOR, -O-Alk-O-R, -O-Alk-OH, -O-Alk-C(NH):NOH, -O-Alk-NRR, -O-Alk-CN, -O-(CH)-Ph, -O-Alk-CO-NRR, -CO-NH-(CH)-COOR, -CO-NH-Alk; Rпредставляет собой H, (C-C)алкил, (C-C)алкилгалогенид, (C-C)циклоалкил или возможно замещенный фенил; A представляет собой -CO-, -SO- или -SO-; Rи Rявляются идентичными или разными, и каждый представляет собой H, (C-C)алкоксил, амино, карбокси, (C-C)алкоксикарбонил, -OH, -нитро, гидроксиамино, -Alk-COOR, -NRR, -NH-Alk-COOR, -NH-COO-Alk, -N(R)-SO-Alk-NRR, -N(R)-SO-Alk, -N(R)-Alk-NRR, -N(R)-CO-Alk-NRR, -N(R)-CO-Alk, -N(R)-CO-CF, -NH-Alk-HetN, -O-Alk-NRR, -O-Alk-CO-NRR, -O-Alk-HetN или Rи Rсовместно образуют ненасыщенный гетероцикл из 5-6 членов, возможно в форме одной из их фармацевтически приемлемых солей.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200400994A 2002-04-04 2003-04-02 Новые 1,2,3-замещенные производные индолизина, являющиеся ингибиторами факторов роста фибробластов, способ их получения и фармацевтические композиции, содержащие их EA007902B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0204220A FR2838123B1 (fr) 2002-04-04 2002-04-04 Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
PCT/FR2003/001030 WO2003084956A1 (fr) 2002-04-04 2003-04-02 NOUVEAUX DERIVES D'INDOLIZINE 1,2,3 SUBSTITUEE, INHIBITEURS DES FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

Publications (2)

Publication Number Publication Date
EA200400994A1 true EA200400994A1 (ru) 2005-06-30
EA007902B1 EA007902B1 (ru) 2007-02-27

Family

ID=28052118

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400994A EA007902B1 (ru) 2002-04-04 2003-04-02 Новые 1,2,3-замещенные производные индолизина, являющиеся ингибиторами факторов роста фибробластов, способ их получения и фармацевтические композиции, содержащие их

Country Status (34)

Country Link
US (2) US7442708B2 (ru)
EP (1) EP1495023B1 (ru)
JP (1) JP4741799B2 (ru)
KR (1) KR101022138B1 (ru)
CN (1) CN100413863C (ru)
AR (1) AR040404A1 (ru)
AT (1) ATE304013T1 (ru)
AU (1) AU2003240984B2 (ru)
BR (1) BR0309026A (ru)
CA (1) CA2476056C (ru)
CO (1) CO5631442A2 (ru)
DE (1) DE60301570T2 (ru)
DK (1) DK1495023T3 (ru)
EA (1) EA007902B1 (ru)
EC (1) ECSP045338A (ru)
ES (1) ES2247540T3 (ru)
FR (1) FR2838123B1 (ru)
HK (1) HK1074631A1 (ru)
HR (1) HRP20040912B1 (ru)
IL (2) IL163755A0 (ru)
IS (1) IS2475B (ru)
MA (1) MA27297A1 (ru)
ME (2) ME00118B (ru)
MX (1) MXPA04009639A (ru)
NO (1) NO329025B1 (ru)
NZ (1) NZ534786A (ru)
PL (1) PL215265B1 (ru)
RS (1) RS51399B (ru)
SI (1) SI1495023T1 (ru)
TN (1) TNSN04188A1 (ru)
TW (1) TWI335222B (ru)
UA (1) UA78016C2 (ru)
WO (1) WO2003084956A1 (ru)
ZA (1) ZA200406613B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2859997B1 (fr) * 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.
KR101279748B1 (ko) * 2003-11-04 2013-07-04 가부시키가이샤 디나벡크 겐큐쇼 유전자 도입된 수상세포의 제조방법
FR2865934B1 (fr) * 2004-02-05 2006-05-05 Sanofi Synthelabo Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne
JP5296983B2 (ja) * 2004-06-24 2013-09-25 株式会社ディナベック研究所 Ｒｎａウイルスが導入された樹状細胞を含む抗癌剤
AU2005309761A1 (en) * 2004-11-22 2006-06-01 Threshold Pharmaceuticals, Inc. Tubulin binding anti cancer agents and prodrugs thereof
FR2883286B1 (fr) * 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
FR2896247B1 (fr) * 2006-01-13 2008-02-29 Sanofi Aventis Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
EP1891955A1 (en) * 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
US8618300B2 (en) * 2008-09-04 2013-12-31 Boehringer Ingelheim International Gmbh Indolizine inhibitors of leukotriene production
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
EP2270043A1 (en) * 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
CN101648953B (zh) * 2009-09-24 2012-09-05 绍兴文理学院 一种咪唑并[1，2-b]吡咯并[1，2-f]哒嗪衍生物及其制备方法和用途
FR2962438B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
FR2962437B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2967412B1 (fr) * 2010-11-17 2012-12-14 Sanofi Aventis Nouveaux derives d'indolizine, leur preparation et leur application en therapeutique
FR2985258A1 (fr) 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
PL3231803T3 (pl) * 2014-12-10 2020-11-02 Ono Pharmaceutical Co., Ltd. Pochodna dihydroindolizynonu
EP3318563A1 (en) * 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
CN108864083B (zh) * 2018-06-07 2021-05-25 广东药科大学 一类具有抗癌活性的氨基取代吲嗪类化合物及其衍生物
CN110251513A (zh) * 2019-07-03 2019-09-20 南京大学 一种含吡唑的中氮茚化合物在制备抗肿瘤药物中的应用
US11976066B1 (en) 2023-10-23 2024-05-07 King Faisal University Substituted 7-amino-3-(substituted benzoyl)indolizine-1-carboxylates as anti-tubercular agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193926A (en) * 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
US4378362A (en) * 1979-12-06 1983-03-29 S.A. Labaz N.V. Indolizine derivatives and process for preparing the same
FR2528845A1 (fr) * 1982-06-17 1983-12-23 Sanofi Sa Nouveaux derives d'indolizine, leur procede de preparation ainsi que les compositions therapeutiques les contenant
FR2594438B1 (fr) * 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
GB9318790D0 (en) * 1993-09-10 1993-10-27 Fujisawa Pharmaceutical Co Heterocyclic derivatives
BR0010482A (pt) * 1999-05-21 2002-04-23 Bristol Myers Squibb Co Inibidores pirrolotriazìnicos de cinases
JP2005501009A (ja) * 2001-06-06 2005-01-13 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｃａｋインヒビターおよびその使用
FR2859997B1 (fr) * 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
MXPA04009639A (es) 2005-07-13
ME00118B (me) 2010-10-10
NZ534786A (en) 2006-06-30
IL163755A (en) 2010-11-30
EA007902B1 (ru) 2007-02-27
JP4741799B2 (ja) 2011-08-10
HRP20040912B1 (hr) 2012-10-31
CN100413863C (zh) 2008-08-27
ES2247540T3 (es) 2006-03-01
FR2838123B1 (fr) 2005-06-10
IS7413A (is) 2004-08-19
ZA200406613B (en) 2007-12-27
FR2838123A1 (fr) 2003-10-10
IL163755A0 (en) 2005-12-18
AU2003240984B2 (en) 2008-07-31
CA2476056C (fr) 2012-03-06
SI1495023T1 (sl) 2005-12-31
AR040404A1 (es) 2005-04-06
US20090023770A1 (en) 2009-01-22
ECSP045338A (es) 2005-03-10
TNSN04188A1 (fr) 2007-03-12
DE60301570D1 (de) 2005-10-13
CN1649867A (zh) 2005-08-03
EP1495023B1 (fr) 2005-09-07
DK1495023T3 (da) 2005-12-27
CA2476056A1 (fr) 2003-10-16
US7803811B2 (en) 2010-09-28
WO2003084956A1 (fr) 2003-10-16
NO20044156L (no) 2005-01-03
TWI335222B (en) 2011-01-01
PL372812A1 (en) 2005-08-08
UA78016C2 (ru) 2007-02-15
PL215265B1 (pl) 2013-11-29
JP2005532286A (ja) 2005-10-27
RS51399B (en) 2011-02-28
RS86404A (en) 2006-12-15
KR101022138B1 (ko) 2011-03-17
KR20040099388A (ko) 2004-11-26
US7442708B2 (en) 2008-10-28
DE60301570T2 (de) 2006-05-18
TW200306181A (en) 2003-11-16
ATE304013T1 (de) 2005-09-15
CO5631442A2 (es) 2006-04-28
EP1495023A1 (fr) 2005-01-12
IS2475B (is) 2008-12-15
HRP20040912A2 (en) 2004-12-31
AU2003240984A1 (en) 2003-10-20
US20050203126A1 (en) 2005-09-15
BR0309026A (pt) 2005-02-09
NO329025B1 (no) 2010-08-02
MA27297A1 (fr) 2005-05-02
MEP22508A (en) 2010-06-10
HK1074631A1 (en) 2005-11-18

Similar Documents

Publication Publication Date Title
EA200400994A1 (ru) Новые 1,2,3-замещенные производные индолизина, являющиеся ингибиторами факторов роста фибробластов, способ их получения и фармацевтические композиции, содержащие их
ATE374765T1 (de) Substituierte heterocyclische amide
ME00411B (me) Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavistan od natrijuma
EA200400054A1 (ru) Замещенные нафтилиндольные производные в качестве ингибиторов ингибитора активатора плазминогена типа 1 (pai-1)
EA200500814A1 (ru) Производные пирролопиримидина
ATE326453T1 (de) Antithrombotische amide
RU2007147344A (ru) Новые производные 2-азетидинона для лечения гиперлипидемических заболеваний
UY26512A1 (es) Inhibidores no peptídicos de la unión celúlar dependiente de vla - 4 útiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
RU2007147338A (ru) Новые производные 2-азетидинона и их применение в качестве ингибиторов всасывания холестерина для лечения гиперлипидемии
EA200000804A1 (ru) Мета-азациклические соединения аминобензойной кислоты и их производные, являющиеся ингибиторами интегрина
DE69915687D1 (de) Heterocyclische amide als inhibitoren von faktor xa
RS51193B (sr) Hidantoinski derivati korisni kao inhibitori metaloproteinaza
CO5680413A2 (es) Aminoacidos con afinidad por la proteina c2 delta
DE602005017162D1 (de) 3-arylthioindol-2-carbonsäureamidderivate und ihre analoge als hemmer von caseinkinase i
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
PE20040669A1 (es) Derivados de fenilalanina enamida
EA200600898A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200501900A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
ATE373636T1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
EA200501925A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200501557A1 (ru) Новый способ синтеза (2s)-индолин-2-карбоновой кислоты и использование в синтезе периндоприла
EA200600456A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200500716A1 (ru) Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат
EA202192051A1 (ru) Селективный ингибитор протеин-аргинин-метилтрансферазы 5 (prmt5)
EA200601086A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU